CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK’s Medicines and Healthcare Products Regulatory ...
To identify DNA methylation sites associated with hATTR and compare patients affected with the disorder with asymptomatic carriers and noncarriers, they tested more than 700,000 sites in 80 ...
Hereditary transthyretin (hATTR) amyloidosis is a rare progressive disease that is passed from parent to child. It is caused by a mutant form of the transthyretin (TTR) protein that can damage vital ...
– At 9 Months, Vutrisiran Met Primary and All Secondary Endpoints, with Statistically Significant Improvements in Neuropathy, Quality of Life (QoL), and Gait Speed, Relative to Placebo – – In Majority ...
Nearly a year after Intellia Therapeutics showed the world how its CRISPR-based therapy safely edits genes inside a patient, the biotech now has additional clinical data indicating that the ...
The US Food and Drug Administration (FDA) has approved vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in ...
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ ALNY lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary ...
WASHINGTON – Angel says her family has been living with a rare disease they called “the curse” for generations. Known as hATTR Amyloidosis, the life-threatening condition was first accurately ...
– Vutrisiran Met All 18-Month Secondary Endpoints, Including Statistically Significant Improvements in Progression of Neuropathy, Quality of Life (QOL), Gait Speed, Nutritional Status and Overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback